—ABATE Phase 2 Trial Aims to Further Assess Safety and Establish Biological and Clinical Proof-of-Concept for CM-101 as a Potential Treatment for Patients with Systemic Sclerosis— CM-101 is a first-in ...
BridgeBio (NASDAQ:BBIO) said it has submitted a New Drug Application to the FDA for approval of its drug acoramidis for the treatment of ATTR-CM, a potentially fatal disease of the heart muscle.
TEL AVIV, Israel, Feb. 21, 2023 /PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results